secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193805-24-000335
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus FY2023 revenue $169.9M, net loss $26.6M; cash runway extended to Q1 2027
--------------------------------------------------------------------------------

- FY2023 revenue $169.9M (down from $206.0M); net loss $26.6M ($1.00 diluted EPS) vs prior year net income $9.3M ($0.35 EPS).
- Q4 2023 revenue $34.0M (down from $160.3M in Q4 2022, which included $200M CSL upfront); Q4 net loss $8.6M ($0.32 diluted EPS).
- Cash and equivalents $348.9M; cash runway extended to Q1 2027; total CSL milestones received $396M.
- Kostaive (sa-mRNA COVID vaccine) approved in Japan, launch expected in 2024; ARCT-032 Phase 1b interim data expected Q2 2024.
- New STARR vaccine discovery programs for Lyme disease and gonorrhea initiated; ARCT-2138 (LUNAR-FLU) Phase 1 study started.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/0001193805-24-000335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380524000335/e619328_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-000335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer